Medications

FDA: Pulmonary embolism risk up with tofacitinib 10 mg for RA

(HealthDay)—A safety clinical trial has revealed that tofacitinib (Xeljanz, Xeljanz XR) 10 mg twice daily is associated with an increased risk for pulmonary embolism (PE) and death among patients with rheumatoid arthritis ...

Diseases, Conditions, Syndromes

Review finds antibiotic development increased, but insufficient

While the pipeline of new antibiotics has improved over the past six years, momentum in the development of new infection-fighting agents remains inadequate and could take a significant downturn without new incentives, a report ...

Medications

Many drugs made available via FDA expanded access programs

(HealthDay)—Over the past two decades, close to 100 U.S. Food and Drug Administration (FDA)-approved drugs and biologics were made available before FDA approval through expanded access programs, according to a study published ...

Oncology & Cancer

New cancer immunotherapy drugs rapidly reach patients after approval

The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study. The finding suggests that cancer immunotherapies ...

Diseases, Conditions, Syndromes

FDA OKs vagus nerve stimulator to treat cluster headaches

(HealthDay)—A new noninvasive device, gammaCore, which works to reduce cluster headache pain by transmitting mild electrical stimulation to the vagus nerve through the skin on the neck, has been approved by the U.S. Food ...

page 8 from 18